This approach could significantly improve the accuracy of PSA-based testing for PCa in clinic practice, offering a way to more personalized and effective diagnostic tools, especially in patients harboring aggressive prostate cancer, even with low PSA levels or a negative MRI results. The gene discussed is KLK3; the disease is Familial prostate cancer.